Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RNVA is the parent company. The $2.5 million note receivable and those preferred share series are clearly in play in RNVAs financial restructuring. Who knows yet exactly what is being negotiated, but investors need to be aware that improvements in the RNVA share structure are happening as we speak.
More restructuring of debt and "other securities" in the works according to the same release. The $2.5 million Innovaqor note is a receivable. Synergy built in as INQR revenue to soar along with RNVA upon Jamestown reopening. Company guidance already points to record Q4 revenue. Buyback of corporate equity in some form appears inevitable.
RNVA should follow a (revenue-driven) pattern similar to DPLS.
See DPLS '20-21 revenue-driven breakout chart.
Expecting news on:
- More restructuring of debt and "other securities." ($2.5 million note receivable)
- Reaffirming previous company guidance for record revenues in Q4 including new revenue post-opening of the Myrtle Recovery Center.
- Reopening the Jamestown hospital under the CAH model. (Jamestown did $86 million PY in revenue before closing. Company guidance suggests $30-40 million PY from CAH reimbursable services after reopening.)
This link is still a good source for 000 chart reads based on historical OTC market data: http://www.stockta.com/cgi-bin/analysis.pl?symb=RNVA&cobrand=&mode=stock
When major indices break records, investors begin looking for bargains OTC. RNVA is the bargain hunter's dream and the bottom feeder's cream.
$2.5 million worth of corporate equity is in one note receivable. That is clearly in play in the CEOs ongoing restructuring of debt and "other securities." Balance sheet and share structure improvements happening as we speak. Buy 'em.
Corporate equity shifted from (some) preferred shares to common shares. The dilution happened a long time ago when the preferred share agreement was made. A larger percentage of corporate equity is now in common shares. I'm okay with that.
That's how the P/L is trending. The debt restructuring so far will add $1.5 million to the 2024 bottom line. The company has not backed off its revenue guidance which translates to a recordbreaking Q4 and revenue doubling in 2024. New revenue stream from Myrtle Recovery Center began in Q4. News on more restructuring of debt "and other securities" to come, (share buyback maybe?) including the disposition of that $2.5 million note receivable. News also coming on replication of the CAH model at Jamestown. That's all in the cards already.
Corporate equity buyback in some form far more likely. The $2.5 million note receivable raises some very interesting possibilities.
News imminent on more balance sheet improvements, share structure improvements, and the Jamestown reopening under the CAH model. Might reaffirm company guidance for record revenues in Q4 too.
The impact of Myrtle Recovery Center revenue is only now beginning to be felt. Will add a huge revenue boost to the Q4 P/L and will continue to grow at least through 2024.
You could be right. I decided to take a break from this board until I saw an indicator. The accumulation to masturbation ratio definitely improved yesterday.
Actually, that was a very desirable 10-Q. $14.84 million in 2023 revenue and over $1.5 million in profit through Q3 with earlier company guidance of at least $5 million in revenue to come in Q4, maybe much more than that. The 10-Q showed all the Myrtle admin and staffing cost ahead of revenues not to begin until Q4 with about $5.25 million in receivables at the end of the quarter. It showed aggressive debt reduction ahead of the debt restructuring that will save over $1.5 million annually beginning in Q4. Great 10-Q looking at all the moving parts.
Good observation. Could have done that any day over the last few months.
Restructuring debt "and other securities" will continue to be a fluid thing for months to come. Several newsworthy improvements to the balance sheet and share structure are foreseeable and practically inevitable with this kind of revenue growth and forward earnings. The items included in the $5.25 million in receivables at the end of Q3 are in play in that regard.
Company guidance of $50-60 million in 2024 revenues. Pennyland.
And the glass slipper fits. Over $1.5 million in 2023 profit through Q3 with debt reduction over $2 million and about $5.25 million in receivables due at the end of the quarter. Then debt restructuring saving over $1.5 million in debt cost per year (matching this year's profit to date). Further restructuring of debt "and other securities" to come while continuing to double revenues YOY. Ready for the Ball, I would say.
By that logic there would be no profitable publicly traded companies. All would go private.
The end of the quarter, the end of the year, the beginning of next year, the middle of next year, the end of next year, and the beginning of the year after that. Those are my horizons. I don't give a flip about the end of the day.
Demand for Myrtle Recovery Center mental health services is extremely high. Just look at all the posts on this board from people who need it. I'm more optimism about RNVA than ever. About to get to the good part.
They aren't RNVAs shares to buy or sell. Not yet anyway. You keep raising the same questions, but the answers are right in front of your nose. It is as if you are oblivious to all that is public info. Namely this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173245066
You have the picture. The company has been very aggressive in applying the strong positive cash flow this year to paying down and restructuring debt. $1.5 million per year in debt cost savings yet to come. That's nothing to sneeze at. In being so aggressive, the company got out a little ahead of receivables at the end of Q3. No big deal. I agree with putting first priority on improving the balance sheet.
Now, what's the next priority? Share structure, of course. RNVA is in a position to begin buying back what's left of some preferred share series and retiring the damned things. Restructuring debt "and other securities" is on the table. (CEO) News on that to come.
More news on more revenue and earnings growth to come too. We know that. We can also expect news on Jamestown and CAH approvals there. Damned good bet anyway. Jamestown was doing $86 million in patient revenues before closing. Based on the CEOs guidance, he plans to cherry pick the $30-40 million of that that are CAH reimbursable services. We already know CAH makes the numbers work.
I'll take that agenda over the agenda of trash talkers any day.
The SEC has busted quite a few illegal short selling schemes in the last two or three years. Not enough, I'm sure.
A few big banks and investment firms run the show. That's for sure. They always have, at least as long as I've been in the market. But the FTC is the cop on that beat, not the SEC. It will take some antitrust actions to break them up.
Some large investor (retail or commercial) who is not an OTC junkie will troll the bottom for value and take up a position worth a few hundred thousand in RNVA at some point. Bound to happen IMO. Not much value left on the big boards. Might be one looking at the Health Care industry in particular. The numbers are too good not to attract a whale or two. It may well already have, and we just don't know when the trigger gets pulled.
You may be right about the crypto part, but I like seeing the SEC clean up the OTC exchanges. It will soon benefit RNVA shareholders in a big way. Yes, there are way fewer super waves, but they were almost all driven by insider trading with shareholders in the dark. RNVA has been under an insider trading plan filed the end of last year. No surprises. RNVA corporate governance is good (2 independent directors) and has built an excellent SEC reporting and compliance record. Let the SEC take out the trash:
https://www.sec.gov/news/press-release/2023-234?utm_medium=email&utm_source=govdelivery
That was before RNVA netted $14.84 million in revenues and $1.54 million in earnings (profit) this year through Q3, while reducing liabilities by $2.25 million and completing expansion to add swing bed and Myrtle Recovery Center operations (new revenue beginning in Q4) and ending the quarter with over $5 million in receivables.
And financial restructuring:
"In addition, we are in discussions about other potential modifications to debt and other securities in the hope we can secure additional amendments that further improve our overall financial position.”
https://www.globenewswire.com/news-release/2023/10/25/2766659/0/en/RENNOVA-HEALTH-INC-ANNOUNCES-SIGNIFICANT-DEBT-RESTRUCTURING.html
Now would be good.
One billion+ share volume day starts a breakout.
$14.84 million in net 2023 revenues through Q3. $1,54 million in net 2023 earnings (profit) through Q3. Liabilities reduced by $2.25 million through Q3. All while completing expansion to add swing bed and new Myrtle Recovery Center operations with that new revenue yet to come. Over $5 million in receivables at the end of Q3. RNVA doesn't belong in the 000s.
RNVA to reestablish penny stock status and uplist to OTCQB. That's my prediction and I'm sticking to it. RNVA will only need a RS when it's time to uplist to OTCQX or Nasdaq. Based on company guidance, RNVA will have enough revenues in 2025 to qualify for OTCQX or Nasdaq.
"Based on what someone posted" pretty much says it. The market (including disproportional short selling) artificially forced way more dilution than should have been necessary. There is a good side to that though. It means improving balance sheet and restructuring debt "and other securities" are a lot easier on the rebound. It appears to me the goal is to replicate the CAH model at Jamestown (at full cash flow) with the OS landing under 50 billion shares. That would leave 200 billion in reserve for MA contingencies.
RNVA had a great Q3. Carried out Myrtle Recovery Center startup AND continued to improve the balance sheet by more than $2 million per quarter at the same time. Not bad at all. The P/L shows the costs of Myrtle but not the revenues..., yet. Q3 receivables will boost Q4 revenues and/or further improve the balance sheet. Debt restructuring will reduce debt costs by over $320,000 per quarter going forward with more (gradual) improvements to the balance sheet. RNVA on track to continue doubling revenues YOY through 2024 and close out 2023 showing a profit a profit $3-4 million (at least).
RNVA is paying for an independent audit, not something you do if you have something to hide. I think the audit will show all went to legit regular business purposes and/or any instance of misspending was hidden from the RNVA CEO and BoD. Might all come down to a disgruntled employee with no direct knowledge of anything. I've never considered this much of a threat to RNVAs bottom line.
I for one am glad the SEC is cleaning up the OTC exchanges. RNVA corporate governance and SEC compliance is as good as you'll find in a pink sheet. By the way, don't sweat the Q3 P/L. The receivables indicate somewhere between $1-2 million in revenues on the plus side going into Q4 before you even start counting the revenues to actually be generated in Q4. Subtract $300,000 per quarter or so in debt costs beginning in Q4. Add Myrtle revenues where only startup costs were included in Q3 and subtract the sunk costs from that, not to mention the accompanying improvement in the cost ratios. Keep the faith GoodTimes. That was good quarterly report.
Wrong company dude. This is Rennova Health Care, Inc. (RNVA). I don't know what RennovaCare is, but it's not RNVA.